Click Here to return To Results

 

Double-Blind, Randomized, Placebo-Controlled Study of Oral, High-Dose Methylprednisolone in Attacks of MS Neurol 51:529-534, Sellebjerg,F.,et al, 1998 See this aricle in Pubmed Article Abstract There is only limited evidence from adequately controlled clinical trials to support high-dose methylprednisolone therapy for attacks of multiple sclerosis(MS)and none supporting oral administration.We assessed the effect of oral high-dose methylprenisolone therapy in attacks of MS. Twenty-five patients with an attack of MS lasting less than 4 weeks were randomized to placebo treatment.Twenty-six patients received oral methyl- prednisolone.The patients received scores on the Scripps Neurological Rating Scale and Kurtzke Expanded Disability Status Scale.The symptoms were scored on a visual anal scale before treatment and after 1,3 and 8 weeks of treatment.Primary efficacy measures were NRS and VAS scores in the first 3 weeks and changes in NRS score and answers to an efficacy questionnaire administered after 8 weeks of treatment.Changes in the NRS scores among methylprednisolone and placebo treated patients different significantly in the first 3 weeks,and after 8 weeks.VAS scores the first 3 weeks and treatment efficacy after 8 weeks also favored a beneficial effect of methylprednisolone treatments.After 1,3,and 8 weeks 4%,24%and 32%of the placebo group and 31%,54%,and 65%of the methylprednisolone group had improved one point on the Expanded Disability Status Score.No serious adverse events were seen.Oral high-dose methylprednisolone is recommended for managing attacks of MS.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction multiple sclerosis multiple sclerosis,treatment of steroid steroid therapy,CNS treatment and complications with treatment of neurologic disorder

Click Here to return To Results